GlassScriptPhysician profile
Kathryn E Pascucci
NPI 1215233044
$2,014.76
in general payments reported to CMS, 2019-2025
27 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $78.95 · 2021: $30.89 · 2022: $133 · 2023: $590 · 2024: $597 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $261.97 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $257.75 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $239.85 | 2023-2025 | |
| Pfizer INC. | $150.16 | 2019-2025 | |
| Exact Sciences Corporation | $148.86 | 2023-2025 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $139.34 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.38 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $98.27 | 2023-2025 | Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.17 | 2023-2024 | Trulance, Xifaxan |
| Sage Therapeutics, LLC | $67.16 | 2024 | |
| Currax Pharmaceuticals LLC | $50.13 | 2023 | Contrave, Onzetra Xsail |
| Aspira Women'S Health INC | $46.46 | 2024 | Ova1 |
| Allergan, INC. | $38.61 | 2019 | |
| Mylan Pharmaceuticals INC. | $35.41 | 2019 | |
| Lupin INC. | $31.14 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.66 | 2019 | |
| Conmed Corporation | $25.15 | 2024 | Airseal |
| Becton, Dickinson and Company | $24.82 | 2019 | |
| Abbott Laboratories | $23.57 | 2023 | Freestyle Libre 3 |
| Shield Therapeutics INC | $23.28 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $21.47 | 2019 | |
| Organon LLC | $18.85 | 2024 | |
| Millicent US INC | $18.32 | 2025 | Intrarosa, Femring |
| Acella Pharmaceuticals, LLC | $17.32 | 2023 | NP Thyroid 60 |
| Novo Nordisk INC | $16.66 | 2024 | Wegovy |
| Avion Pharmaceuticals | $15.08 | 2019 | |
| Coopersurgical, INC. | $14.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Pascucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.